Syros Pharmaceuticals Inc (SYRS) Expected to Post Earnings of -$0.50 Per Share
Wall Street brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce ($0.50) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.53). Syros Pharmaceuticals reported earnings of ($0.58) per share during the same quarter last year, which would indicate a positive year over year growth rate of 13.8%. The firm is expected to announce its next quarterly earnings report on Monday, March 11th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.87) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.85). For the next year, analysts expect that the firm will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.11) to ($1.80). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.02). The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million.
Syros Pharmaceuticals stock opened at $7.36 on Wednesday. Syros Pharmaceuticals has a 1-year low of $6.25 and a 1-year high of $15.88.
A number of hedge funds have recently modified their holdings of the business. FMR LLC grew its stake in Syros Pharmaceuticals by 3.3% in the 3rd quarter. FMR LLC now owns 5,048,158 shares of the company’s stock worth $60,124,000 after acquiring an additional 161,410 shares in the last quarter. ARK Investment Management LLC grew its stake in Syros Pharmaceuticals by 23.5% in the 3rd quarter. ARK Investment Management LLC now owns 2,221,870 shares of the company’s stock worth $26,462,000 after acquiring an additional 422,317 shares in the last quarter. BlackRock Inc. grew its stake in Syros Pharmaceuticals by 1.9% in the 3rd quarter. BlackRock Inc. now owns 1,613,668 shares of the company’s stock worth $19,219,000 after acquiring an additional 30,037 shares in the last quarter. Millennium Management LLC grew its stake in Syros Pharmaceuticals by 129.3% in the 2nd quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after acquiring an additional 211,696 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Syros Pharmaceuticals by 2.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock worth $4,406,000 after acquiring an additional 8,286 shares in the last quarter. Institutional investors and hedge funds own 60.74% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
See Also: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.